Bioethics News

Questioning Ethics of Costly Drugs for Metastatic Cancer

November 17, 2016

(Medscape) – Many commentators have raised concern about very expensive cancer drugs that offer only a short survival benefit, but a new voice questions the ethics of such treatment. “Spending a six figure sum to prolong a life by a few weeks or months is already unaffordable,” but it is also “inappropriate” for the many cancer patients who “will almost inevitably die from solid tumor metastases,” says Peter Wise, a former consultant physician at Charing Cross Hospital and Imperial College School of Medicine, London, England.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.